Smarter data analysis, faster research, and growing investment are giving artificial intelligence a bigger role in the search for new medicines
Boston, Massachusetts, 15 September 2026 – Artificial intelligence is becoming an increasingly important tool in the search for new medicines, helping researchers examine complex biological information, identify potential drug targets, and explore promising compounds more efficiently. As the technology becomes more practical for pharmaceutical and biotechnology companies, the market for AI in drug discovery is expected to expand rapidly.
The global artificial intelligence in drug discovery market is projected to reach approximately $13.8 billion by 2033, rising from an estimated $2.9 billion in 2026. The market is expected to grow at a compound annual growth rate of about 24.8 percent between 2026 and 2033, according to Grand View Research.
The growth reflects a broader change in how drug research is being conducted. Developing a new medicine traditionally requires years of laboratory research, testing, and clinical development. Researchers must work through enormous amounts of biological and chemical information before a promising candidate can move forward. AI can help organize and analyze this information much faster.
One important application is drug optimization and repurposing. AI systems can examine existing medicines and biological data to identify possible new uses or improve the characteristics of potential treatments. This segment accounted for the largest share of the AI drug discovery market in 2025, showing how strongly companies are using the technology to support existing research processes.
AI is also being used to support preclinical research. Algorithms can help researchers study molecular structures, predict how compounds may interact with biological targets, and identify candidates that deserve further laboratory investigation. By narrowing the number of possibilities earlier, researchers can potentially spend more time and resources on the candidates with stronger potential.
The technology is gaining attention across several therapeutic areas. Oncology remains one of the largest areas of activity, as cancer research generates enormous amounts of genetic, molecular, and clinical data. AI can help researchers identify patterns within this information and support the search for more targeted approaches.
Pharmaceutical and biotechnology companies are expected to remain major users of AI drug discovery technologies. Research institutions and contract research organizations are also becoming important participants as access to advanced computing, cloud infrastructure, and specialized AI platforms expands.
Investment is another factor supporting the market’s growth. AI is increasingly being viewed as a practical research tool rather than simply an emerging technology. Partnerships between technology companies, pharmaceutical businesses, biotechnology firms, and research organizations are creating new ways to combine computational tools with laboratory work.
AI does not remove the complexity of drug development. A promising computer prediction still needs to be tested in laboratories and evaluated through clinical research. Biology can behave in unexpected ways, and a candidate that appears promising digitally may not produce the same results in real world testing. Human researchers therefore remain central to interpreting results, designing experiments, and making scientific decisions.
The increasing use of AI is instead changing where researchers spend their time. By handling some data intensive tasks, AI can help scientists move more quickly through early stage research and focus their attention on the questions that require deeper scientific judgment.
North America currently leads the global AI drug discovery market, supported by strong pharmaceutical research activity, technology investment, and funding for AI focused biotechnology companies. Asia Pacific is expected to record significant growth as investment in biotechnology, artificial intelligence, and advanced research infrastructure increases.
The projected $13.8 billion market by 2033 points to a larger shift taking place across life sciences. AI is becoming part of the research infrastructure supporting drug discovery, from identifying targets and analyzing molecules to improving drug development strategies. Its ultimate value will depend on how effectively technology and scientific expertise work together, but the direction is becoming increasingly clear: artificial intelligence is moving deeper into the process of discovering tomorrow’s medicines.
